Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Regulation of telomerase reverse transcriptase gene activity by upstream stimulatory factor

Abstract

Upregulation of human telomerase reverse transcriptase (hTERT) transcription accounts for the immortalization of greater than 85% of all human tumor cells. However, the mechanism whereby hTERT expression is activated remains unresolved. Specifically, recent data challenging the role of Myc/Max in E-box-dependent activation of hTERT expression suggests that other E-box-binding proteins regulate hTERT transcription. Indeed, we now demonstrate that two such proteins, upstream stimulatory factor (USF) 1 and 2, readily associate with two E-boxes in the hTERT promoter in vitro and in vivo primarily as heterodimers, whereas Myc/Max does not. The avid binding of USF1/2 heterodimers to these E-boxes occurs in both hTERT-positive and -negative cells. In contrast, USF1/2 activates the hTERT promoter exclusively in hTERT-positive cells in a manner that is enhanced by the coactivator p300 and attenuated upon inhibiting p38-MAP kinase, a known modulator of USF activity. Collectively, our data indicate that USF binding to the hTERT promoter may be transcriptionally neutral, or even repressive, in nonimmortalized hTERT-negative somatic cells, but stimulatory in hTERT-positive cells where USF1/2 contributes to the acquisition and maintenance of immortality.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Aisner DL, Wright WE and Shay JW . (2002). Curr. Opin. Genet. Dev., 12, 80–85.

  • Blackburn EH . (2001). Cell, 106, 661–673.

  • Bosc DG, Goueli BS and Janknecht R . (2001). Oncogene, 20, 6215–6224.

  • Bredemeier-Ernst I, Nordheim A and Janknecht R . (1997). FEBS Lett., 408, 47–51.

  • Breen GA and Jordan EM . (1999). Biochim. Biophys. Acta, 1428, 169–176.

  • Dhaene K, Wauters J, Weyn B, Timmermans JP and van Marck E . (2000). J. Pathol., 190, 80–85.

  • Dillner NB and Sanders MM . (2002). J. Biol. Chem., 277, 33890–33894.

  • Drissi R, Zindy F, Roussel MF and Cleveland JL . (2001). J. Biol. Chem., 276, 29994–30001.

  • Ducrest AL, Amacker M, Mathieu YD, Cuthbert AP, Trott DA, Newbold RF, Nabholz M and Lingner J . (2001). Cancer Res., 61, 7594–7602.

  • Ducrest AL, Szutorisz H, Lingner J and Nabholz M . (2002). Oncogene, 21, 541–552.

  • Galibert MD, Carreira S and Goding CR . (2001). EMBO J., 20, 5022–5031.

  • Goodman RH and Smolik S . (2000). Genes Dev., 14, 1553–1577.

  • Gregor PD, Sawadogo M and Roeder RG . (1990). Genes Dev., 4, 1730–1740.

  • Heckert LL . (2001). Mol. Endocrinol., 15, 704–715.

  • Hiyama E and Hiyama K . (2002). Oncogene, 21, 643–649.

  • Horikawa I, Cable PL, Mazur SJ, Appella E, Afshari CA and Barrett JC . (2002). Mol. Biol. Cell, 13, 2585–2597.

  • Horiuchi K, Fujimoto D, Fukushima M and Kanai K . (1981). Cancer Res., 41, 1488–1491.

  • Janknecht R . (2002). Histol. Histopathol., 17, 657–668.

  • Kumari D and Usdin K . (2001). J. Biol. Chem., 276, 4357–4364.

  • Kuo MH and Allis CD . (1999). Methods, 19, 425–433.

  • Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, Yutsudo M, Ariga H and Inoue M . (2000). Nucleic Acids Res., 28, 669–677.

  • Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, Strickler JE, McLaughlin MM, Siemens IR, Fisher SM, Livi GP, White JR, Adams JL and Young PR . (1994). Nature, 372, 739–746.

  • Liu SL, Rand A, Kelm Jr RJ and Getz MJ . (2000). Oncogene, 19, 3352–3362.

  • Muhlethaler-Mottet A, Di Berardino W, Otten LA and Mach B . (1998). Immunity, 8, 157–166.

  • Pearson KL, Hunter T and Janknecht R . (1999). Biochim. Biophys. Acta, 1489, 354–364.

  • Poole JC, Andrews LG and Tollefsbol TO . (2001). Gene, 269, 1–12.

  • Sirito M, Lin Q, Maity T and Sawadogo M . (1994). Nucleic Acids Res., 22, 427–433.

  • Sirito M, Walker S, Lin Q, Kozlowski MT, Klein WH and Sawadogo M . (1992). Gene Expr., 2, 231–240.

  • Viollet B, Lefrancois-Martinez AM, Henrion A, Kahn A, Raymondjean M and Martinez A . (1996). J. Biol. Chem., 271, 1405–1415.

  • Won J, Yim J and Kim TK . (2002a). FASEB J., 16, 1943–1945.

  • Won J, Yim J and Kim TK . (2002b). J. Biol. Chem., 277, 38230–38238.

  • Yago M, Ohki R, Hatakeyama S, Fujita T and Ishikawa F . (2002). FEBS Lett., 520, 40–46.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ralf Janknecht.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goueli, B., Janknecht, R. Regulation of telomerase reverse transcriptase gene activity by upstream stimulatory factor. Oncogene 22, 8042–8047 (2003). https://doi.org/10.1038/sj.onc.1206847

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206847

Keywords

This article is cited by

Search

Quick links